Larimar Therapeutics (LRMR) Other Accumulated Expenses (2013 - 2025)

Larimar Therapeutics' Other Accumulated Expenses history runs 13 years deep, the most recent figure standing at $777000.0 for Q4 2025.

• Quarterly Other Accumulated Expenses rose 38.5% year-over-year to $777000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $777000.0 (up 38.5% YoY) and the FY2025 annual result came in at $777000.0, up 38.5% from the prior year.
• Other Accumulated Expenses was $777000.0 for Q4 2025 at Larimar Therapeutics, down from $881000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.1 million in Q2 2024 and bottomed at $105000.0 in Q1 2021.
• A 5-year average of $577150.0 and a median of $540000.0 in 2022 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Other Accumulated Expenses slumped 69.18% — and 2022, when it surged 416.56%.
• Larimar Therapeutics' Other Accumulated Expenses stood at $452000.0 in 2021, then dropped by 2.43% to $441000.0 in 2022, then declined by 3.17% to $427000.0 in 2023, then soared by 31.38% to $561000.0 in 2024, then soared by 38.5% to $777000.0 in 2025.
• Business Quant data shows LRMR's Other Accumulated Expenses at $777000.0 in Q4 2025, $881000.0 in Q3 2025, and $662000.0 in Q2 2025.